JGC
VKTX icon

J. Goldman & Co’s Viking Therapeutics VKTX Stock Holding History

J. Goldman & Co’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-20,000
Closed -$704K – 898
2025
Q4 		$704K Buy
+20,000
New +$709K 0.02% 430
2023
Q4 		– Sell
-67,500
Closed -$747K – 486
2023
Q3 		$747K Buy
+67,500
New +$965K 0.03% 251

Other funds holding VKTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

J. Goldman & Co's VKTX Position: Q1 2026 in Review

J. Goldman & Co reduced its Viking Therapeutics (VKTX) stake by 55% in Q1 2026, selling an estimated $590K and leaving 15,294 shares worth $498K. The position accounts for 0.01% of the portfolio, ranked #505.

J. Goldman & Co first reported a position in VKTX in Q2 2018 and has held it in 7 quarters since. The position peaked at $1.18M in Q4 2025. 410 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

  • J. Goldman & Co held 15,294 shares of Viking Therapeutics worth $498K as of Q1 2026.
  • J. Goldman & Co sold 18,364 Viking Therapeutics shares in Q1 2026, an estimated $590K.
  • Viking Therapeutics made up 0.01% of J. Goldman & Co's portfolio in Q1 2026, its #505 holding.
  • J. Goldman & Co first reported a position in Viking Therapeutics in Q2 2018 and has held it in 7 quarters since.
  • J. Goldman & Co's Viking Therapeutics position peaked at $1.18M in Q4 2025.
  • 410 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on J. Goldman & Co's 13F filing for Q1 2026, filed 15 May 2026.